Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Epilepsy tiagabine

The EEG effects of valerian are most concordant with those of tiagabine, a GABA uptake inhibitor used to treat epilepsy. Tiagabine also increases slow-wave sleep, but unlike valerian has little or no effect on REM (Lancel et al. 1998). GABAA agonists also tend to have this effect. [Pg.221]

In parallel with the identification of distinct transporters for GABA there has been continued interest in the development of selective blockers of these transporters and the therapeutic potential that could result from prolonging the action of synaptically released GABA. It has been known for a long time that certain pro-drugs of nipecotic add (e.g. nipecotic acid ethyl ester) are able to cross the blood-brain barrier and are effective anticonvulsants in experimental models of epilepsy. More recently, several different systemically active lipophillic compounds have been described that act selectively on GAT-1, GAT-2 or GAT-3 (Fig. 11.4). Of these, tiagabine (gabitiil), a derivative of nipecotic acid that acts preferentially on GAT -1, has proved clinically useful in cases of refractory epilepsy. [Pg.231]

Richens, A., Chadwick, D. W., Duncan, J. S., et al. (1995) Adjunctive treatment of partial seizures with tiagabine a placebo-controlled trial. Epilepsy Res. 21, 37 42. [Pg.189]

Seizures in patients without epilepsy Postmarketing reports have shown that tiagabine use has been associated with new onset seizures and status epilepticus in patients without epilepsy. [Pg.1261]

Status epilepticus Among the patients treated with tiagabine across all epilepsy studies (controlled and uncontrolled), 5% had some form of status epilepticus. Of the 5%, 57% of patients experienced complex partial status epilepticus. A critical risk factor for status epilepticus was the presence of the condition history 33% of patients with a history of status epilepticus had recurrence during tiagabine treatment. [Pg.1262]

Sudden unexpected death in epilepsy (SUDEP) There have been as many as 10 cases of SUDEP during the clinical development of tiagabine among 2531 patients with epilepsy (3831 patient-years of exposure). [Pg.1262]

Generalized weakness Moderately severe to incapacitating generalized weakness has been reported following administration of tiagabine in approximately 1% of patients with epilepsy. The weakness resolved in all cases after a reduction in dose or discontinuation of tiagabine. [Pg.1263]

Fritz N, Glogau S, Hoffmann J, Rademacher M, Eiger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005 6(3) 373-81. [Pg.364]

Adkins JC and Noble S. Tiagabine A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998 55 437-460. [Pg.384]

Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 2000 41(l) 23-8. [Pg.664]

Sackellares JC, Krauss G, Sommerville KW, Deaton R. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 2002 43(4) 394-8. [Pg.702]

Tiagabine is itself an augmenfing agenf for numerous ofher anficonvulsanfs in freafing epilepsy... [Pg.457]

Status epilepticus in epilepsy (unknown if associated with tiagabine use)... [Pg.458]

Clearance of tiagabine is increased if taken with an enzyme-inducing antiepileptic drug (e.g., carbamazepine, phenobarbital, phenytoin, primidone) and thus plasma levels are reduced however, no dose adjustments are necessary for treatment ot epilepsy as the dosing recommendations for epilepsy are based on adjunctive treatment with an enzyme-inducing antiepileptic drug... [Pg.459]

Visual field defects associated with various antiepUeptic drugs (carbamazepine, diazepam, gabapentin, pheny-toin, tiagabine, and vigabatrin) have been reviewed (19). The true frequency is unknown, but in a retrospective study in 158 patients with partial epilepsy visual field defects were detected in 21 (13%) 13 patients had concentric visual field constriction without subjective spontaneous manifestations. Of these 13 patients, 9 were taking vigabatrin. [Pg.277]

The effects of tiagabine have been studied in a 4-month, single-blind study in 52 children over the age of 2 years with different syndromes of refractory epilepsy (5). Adverse events, mostly mild to moderate, were reported by 39% of the children during the single-blind placebo period and by 83% of the children during tiagabine treatment. The events predominantly affected the nervous system weakness (19%), nervousness (19%), dizziness (17%), and somnolence (17%) were the most common. One child had hallucinations that responded to dosage reduction. Only three children withdrew because of adverse events. [Pg.3419]

After an increase in tiagabine dose to 32 mg/day, a 28-year-old woman with partial epilepsy developed a prolonged and disoriented state associated with generalized spike-and-wave discharges on the electroencephalogram. Tiagabine was withdrawn and the status did not recur. [Pg.3419]

There have been cases of generalized non-convnlsive status epilepticus in patients with chronic partial epilepsy treated with tiagabine, on one occasion specifically associated with frontal lobe discharges (15). [Pg.3420]

Tiagabine 0.45-40.57 mg/kg/day was associated with longstanding non-convulsive status epilepticus in three girls, two aged 12 years and one aged 17 years, with refractory localization-related epilepsy (17). Resolntion followed withdrawal of tiagabine or a reduction in dosage. [Pg.3420]

The effect of tiagabine on visual function has been stndied in 15 patients with chronic partial epilepsy treated for 23-55 months with tiagabine monotherapy after fail-nre with standard antiepileptic drug monotherapy (23). Three patients had localized field losses (two qnadranta-nopic and one hemianopic) from earlier brain lesions. Tiagabine had no effect on visual fields but acquired color vision defects were found in seven of 14 patients contrast sensitivity was unaffected. [Pg.3420]

Leppik IE, Gram L, Deaton R, SommerviUe KW. Safety of tiagabine summary of 53 trials. Epilepsy Res 1999 33(2-3) 235-46. [Pg.3421]

Uldall P, Bulteau C, Pedersen SA, Dulac O, Lyby K. Tiagabine adjunctive therapy in children with refractory epilepsy a single-blind dose escalating study. Epilepsy Res 2000 42(2-3) 159-68. [Pg.3421]


See other pages where Epilepsy tiagabine is mentioned: [Pg.340]    [Pg.348]    [Pg.349]    [Pg.406]    [Pg.452]    [Pg.339]    [Pg.67]    [Pg.376]    [Pg.269]    [Pg.218]    [Pg.690]    [Pg.508]    [Pg.279]    [Pg.337]    [Pg.87]    [Pg.71]    [Pg.181]    [Pg.207]    [Pg.274]    [Pg.277]    [Pg.3419]    [Pg.3419]    [Pg.3420]   
See also in sourсe #XX -- [ Pg.1042 ]




SEARCH



Epilepsies

Tiagabin

Tiagabine

© 2024 chempedia.info